Reducing data variability means increasing trial power, improving data analysis and empowering decision-making. It means that clinical trials need to be repeated less often. It means that drug programs are more likely to succeed. Most importantly, it means assuring and accelerating the delivery of medicines to patients.
Predict each clinical trial patient's placebo responsiveness to increase clinical trial power and reduce the risk of inconclusive trials
Find out more...
Characterize clinical trial patient’s individual response to stress and change in trial conduct during the COVID-19 pandemic.
Find out more...
De-Risk Drug Development
The pharmaceutical, biotechnology and medical device industries have been plagued by high rates of failure in Phase 2 and Phase 3 due to the inability to demonstrate therapeutic efficacy. Over time, this has resulted in clinical trials that are longer, more expensive and more burdensome for patients. It has also resulted in the premature discontinuation of the development of efficacious drugs. Tools4Patient has developed platform technologies that address key sources of data variability to improve the success rate of clinical trials and de-risk the drug development process.
Tools4Patient's Mission
Tools4Patient is passionate about empowering pharmaceutical, biotech and medical device companies to make the right decisions at the right time, ultimately aiming to accelerate patient access to new therapeutics.
The company was founded by long-time colleagues with decades of experience in the pharmaceutical industry who set out to tackle some of the most challenging issues that prevent drugs from reaching the marketplace.
Latest News and Events from Tools4Patient
STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October 13, 2020. The
Find out more...Global partnerships that drive life science dealmaking. Bio-Europe Digital is the ideal platform to schedule virtual partnering meeting but also
Find out more...Tools4Patient
Reducing clinical data variability. Empowering better decision making. Accelerating the launch of therapeutics to market.